公开(公告)号：US20190270741A1

公开(公告)日：2019-09-05

申请号：US16347849

申请日：2017-11-07

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Pratik DEVASTHALE ,  Fang MOORE ,  Guohua ZHAO ,  Susan Nicole PIENIAZEK ,  Kumaravel SELVAKUMAR ,  Suresh DHANUSU ,  Manoranjan PANDA ,  Lawrence R. MARCIN

IPC: C07D471/04 ,  A61P35/00 ,  A61P1/16 ,  A61P13/12 ,  A61P11/00

Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to αv-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of αv-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

公开(公告)号：US20180072728A1

公开(公告)日：2018-03-15

申请号：US15558724

申请日：2016-03-17

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Lawrence R. MARCIN ,  Stephen T. WROBLESKI ,  Murali T.G. DHAR

IPC: C07D471/14

CPC classification number: C07D471/14

Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein: X is CR6 or N; W is: (i) —(CR3R3)1-4— or (ii) —(CR3R3)x-Y—(CR3R3)y-; and Y, R1, R2, R3, R5, R6, R7, x, and y are define herein. Also disclosed are methods of using such compounds as modulators of TNFα, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.